Pharmacological interventions for vascular calcification in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials
- 1Department of Nephrology, Shaoxing Central Hospital, China
Abstract
Objective: To evaluate the efficacy of pharmacological interventions for vascular calcification and related outcomes in patients with chronic kidney disease.
Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to 1 May 2026. Randomized controlled trials comparing pharmacological interventions with placebo, standard care, or other controls in patients with chronic kidney disease were included. Primary outcomes were imaging-defined measures of vascular calcification, including coronary artery calcification Agatston score, percentage coronary artery calcification progression, coronary artery calcification volume change, and abdominal aortic calcification progression. Secondary outcomes included carotid intima-media thickness, serum calcification propensity (T50), arterial stiffness, calcification-related biomarkers, mineral metabolism parameters, and all-cause mortality. Mean differences or odds ratios with 95% confidence intervals were pooled using fixed- or random-effects models according to heterogeneity.
Results: Twenty-eight randomized controlled trials involving 6330 participants were included. Pharmacological interventions did not significantly reduce the coronary artery calcification Agatston score, coronary artery calcification progression, coronary artery calcification volume change, abdominal aortic calcification progression, arterial stiffness, or all-cause mortality. Significant effects were observed for left carotid intima–media thickness (mean difference −0.06 mm, 95% confidence interval: −0.10 to −0.02), common carotid artery intima–media thickness (mean differences −0.07 mm, 95% confidence interval: −0.14 to −0.00), T50 change (mean differences 50.25 min, 95% confidence interval: 34.68–65.82), and dephosphorylated–uncarboxylated matrix Gla protein (mean differences −504.97 pmol/L, 95% confidence interval: −789.72 to −220.22). Most mineral metabolism parameters were unchanged, although ionized calcium was modestly reduced. Effects varied by pharmacological strategy, supporting intervention-specific interpretation.
Conclusions: Pharmacological interventions did not show consistent benefits on imaging-defined vascular calcification in patients with chronic kidney disease. Improvements in T50, dephosphorylated-uncarboxylated matrix Gla protein, and selected carotid intima–media thickness measures suggest pathway-specific biological or vascular effects that may precede or not directly translate into reduced structural calcification. Further randomized controlled trials with standardized imaging endpoints, longer follow-up, and clinically relevant subgroup reporting are needed to determine which therapeutic strategies provide meaningful vascular benefits.
Related
- Effectiveness of Non-Pharmacological Interventions for Fatigue in Long COVID: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Clinical similarity, economic divergence: cost-effectiveness and population health implications of dietary, pharmacological, and exercise interventions in older adults with type 2 diabetes: a secondary analysis of a randomized controlled trial.
- Effects of exercise interventions on executive function in adolescents: a systematic review and three-level meta-analysis of randomized controlled trials
- Exercise-based rehabilitation interventions for kinesiophobia after total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials.
- Global Perspective on the Outcomes of Dietary Pattern and Nutrient-Based Interventions for Heart Failure: A Systematic Review of Randomized Controlled Trials
BibTeX
@article{cao2026pharmacological,
title = {{Pharmacological interventions for vascular calcification in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials}},
author = {Cuiyun Cao and Hanxu Song and Wei Shan and Wei Huang},
journal = {The Journal of International Medical Research},
year = {2026},
month = sep,
doi = {10.1177/03000605261491505},
url = {https://doi.org/10.1177/03000605261491505},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Pharmacological interventions for vascular calcification in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials
AU - Cuiyun Cao
AU - Hanxu Song
AU - Wei Shan
AU - Wei Huang
PY - 2026
DA - 2026/09/28
JO - The Journal of International Medical Research
DO - 10.1177/03000605261491505
UR - https://doi.org/10.1177/03000605261491505
AB - Objective: To evaluate the efficacy of pharmacological interventions for vascular calcification and related outcomes in patients with chronic kidney disease. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to 1 May 2026. Randomized controlled trials comparing pharmacological interventions with placebo, standard care, or other controls in patients with chronic kidney disease were included. Primary outcomes were imaging-defined measures of vascular calcification, including coronary artery calcification Agatston score, percentage coronary artery calcification progression, coronary artery calcification volume change, and abdominal aortic calcification progression. Secondary outcomes included carotid intima-media thickness, serum calcification propensity (T50), arterial stiffness, calcification-related biomarkers, mineral metabolism parameters, and all-cause mortality. Mean differences or odds ratios with 95% confidence intervals were pooled using fixed- or random-effects models according to heterogeneity. Results: Twenty-eight randomized controlled trials involving 6330 participants were included. Pharmacological interventions did not significantly reduce the coronary artery calcification Agatston score, coronary artery calcification progression, coronary artery calcification volume change, abdominal aortic calcification progression, arterial stiffness, or all-cause mortality. Significant effects were observed for left carotid intima–media thickness (mean difference −0.06 mm, 95% confidence interval: −0.10 to −0.02), common carotid artery intima–media thickness (mean differences −0.07 mm, 95% confidence interval: −0.14 to −0.00), T50 change (mean differences 50.25 min, 95% confidence interval: 34.68–65.82), and dephosphorylated–uncarboxylated matrix Gla protein (mean differences −504.97 pmol/L, 95% confidence interval: −789.72 to −220.22). Most mineral metabolism parameters were unchanged, although ionized calcium was modestly reduced. Effects varied by pharmacological strategy, supporting intervention-specific interpretation. Conclusions: Pharmacological interventions did not show consistent benefits on imaging-defined vascular calcification in patients with chronic kidney disease. Improvements in T50, dephosphorylated-uncarboxylated matrix Gla protein, and selected carotid intima–media thickness measures suggest pathway-specific biological or vascular effects that may precede or not directly translate into reduced structural calcification. Further randomized controlled trials with standardized imaging endpoints, longer follow-up, and clinically relevant subgroup reporting are needed to determine which therapeutic strategies provide meaningful vascular benefits.
SN - 0300-0605
SN - 1473-2300
ER -